Jean-Paul Borg
  • E-mail :[email]
  • Phone : 04 86 97 72 01
  • Location : Marseille, France
Last update 2022-11-07 23:40:14.891

Jean-Paul Borg PharmD, PhD (Immunology)

Course and current status

Jean-Paul BORG, PU-PH CE2,

PharmD, PhD, born February 4th, 1966

 Affiliations: Aix-Marseille University, Faculty of Pharmacy (Cell Biology) and Institut Paoli-Calmettes (Hospital, Department of Pathology), Marseille, France

Research: Centre de Recherche en Cancérologie de Marseille U1068 Inserm, U7258 CNRS, Aix-Marseille Université U105, Institut Paoli-Calmettes, Marseille, France



1999            License to conduct independent research (Univ Aix-Marseille II)

1995            PharmD, Diploma of Pathology (Faculty of Pharmacy, Marseille)

1995            PhD in Immunology (Faculté des Sciences de Marseille-Luminy) 

1992                Master of Immunology (Faculté des Sciences de Marseille-Luminy)

1990-1991    Military service

1989-1991    Internship of Biomedical Analysis (south of France).

1984-1988      PharmD, Faculty of Pharmacy, Marseille

1984              Baccalauréat (Mathematics, Physics)


Career history

2019-…           Coordinator, Institute Cancer-Immunology, Aix-Marseille University

2013-…           Vice-Dean Research, Faculty of Pharmacy, Marseille

2012-…           Director,Centre de Recherche en Cancérologie de Marseille (CRCM)

2012-2017    Scientific Director of SIRIC Marseille

2012                 Full Professor Cell Biology (PU-PH), Exceptional Class

2011-…           Full Professor Cell Biology and Pathology, first class (CNU 82)

                    Director of Center of Cancer Biology – Institut-Calmettes (IPC)

2007-…           Scientific Director - IPC 

2006-2011      Professor Cell Biology, first class (CNU 41) 

2007-2010      Coordinator of Canceropôle Provence Alpes Côte d’Azur

2002-2006      Senior Investigator INSERM (DR2 in 2002, DR1 in 2006)

2001-….        Director of the Laboratory of Molec.Pharmacology, IPC

1998-2002     Junior Investigator INSERM (CR1), U119 INSERM, Marseille

1995-1998     Post-doctoral fellow, HHMI, Ann Arbor, MI (B. Margolis)

1992-1995     PhD Immunology, U119 INSERM, Marseille (D. Birnbaum)

1991             Master of Immunology, CIML (M. Pierres)

1988-1995     Internship of Pathology (Public Hospital, Marseille)

1988-1991        Short term replacements (pharmacy, pathology lab)


National and international activities

- Director of Institute of Cancer & Immunology (Aix-Marseille University) (2019-….)

- Director of CRCM (2012-…): 21 teams INSERM/CNRS/University (450 people)

- Group leader (2004-…): 15 people including 5 senior investigators

- Chairman of the Cell Biology Department at Faculty of Pharmacy, Marseille (2006-…)

- Board member of the Master « Biology Sciences », Oncology (2004-…) (45 Masters/year)

- Co-Head of the IBiSA Marseille Proteomic platform (2008-…)

- Member of the Scientific Advisory Board of INSERM (2022-…)

- Member of the Scientific Advisory Board of Foundation ARC (2023-….)

- Member of the Interdisciplinary Council of Aix-Marseille University (2023-….)

- Head of the Biopathology Center of Institut Paoli-Calmettes (75 people) 2012 -2022)

- Scientific Director of SIRIC Marseille (2012-2017) (750 people)

- Coordinator of the Pole of Health and Life Sciences, Aix-Marseille University (2013-2019)

- Coordinator of Canceropôle Provence Alpes Côte d’Azur (2007-2010)

- President of the Scientific Advisory Board (South East) of Fondation ARC (2007-2010)

- Member of the Scientific Advisory Board of Centre Léon Bérard (2004-….), Prix Ruban rose (2017-…), la Ligue Nationale Contre le Cancer (2012-2020), Comité de Pilotage de Marseille Immunopole (2010-2019), de l’Institut Gustave Roussy (Avenir teams) (2017-2019), Section 24 CNRS (2015-2020), Canceropole PACA (2011-2017), ANSM (french FDA) (2012-2015), Fondation pour la Recherche Médicale (2007-2012), Conseil Régional PACA (2005-2010), La Ligue Nationale Contre le Cancer (2001-2004), ITMO Cancer INSERM/CNRS (2010-2017).

- Expert for funding agencies: ARC, INCa, la Ligue Contre Le Cancer, FRM, CNRS, Association for International Cancer Research, Welcome Trust, NIH RO1 grants, ,….

- Expert for scientific journals: eLife, EMBO Journal, Current Biology, EMBO Reports, Nature Communications, Molecular and Cellular Biology, Journal of Biological Chemistry, Oncogene, Journal of Cell Science, ….

Awards: Scientific Award Var 2001 Ligue Contre Le Cancer “Dr Joseph Amalric”; Scientific Award Junior Team 2005 « Festival des Sciences et Technologies », Marseille; Senior Member of Institut Universitaire de France (2013-2023); Award Pink Ribbon, breast cancer research (2016); Grand Prix de l’Académie Nationale de Pharmacie (2017) ;Chevalier de l’Ordre des Palmes Académiques (2017)

 Scientific coordination :

- Meeting organization: Conference Philippe Laudat « Molecular complexes in physiology and physiopathology » 2002, St Raphael, France; One Day meeting « Tyrosine Kinases » 2004; LKB1 meeting, 2010, Marseille; over 50 meetings of Canceropole PACA, CRCM, Aix-Marseille University, Faculty of Pharmacy in the past 20 years.

- PhD Thesis under my supervision: Hiroko Saito (2002), Fanny Jaulin-Bastard (2004), Jean-Yves Métais (2005), Christel Navarro (2005), Claire Nourry (2005), Thomas Prébet (2009), Edwige Belotti (2010), Anne-Catherine Lhoumeau (2013), Wilfried Traoré (2014), Sébastien Martinez (2016), Monica Wagner-Silveira-Wagner (2019), Alexandra Walton (2020), Marta Montserrat-Gomez (2020), Laetitia Ganier (2021), Alix Jaeger (ongoing), Jean Monatte (ongoing), Yanis Saidini (ongoing), Julia Koren (ongoing), Louis Guiraud (ongoing).

- 12 postdocs under my supervision since 2004.

Scientific production: - H factor: 51, 7984 citations / 150 publications / Patents: 4

 Fundings: The team is supported by the following competitive fundings (total >4.000 K€):

- national (4.000K€): Label Ligue Nationale Contre le Cancer (2004-2024), 3 Projets Libres INCa (2012-2016, 2015-2018, 2017-2020), Fondation de France (2008-2009, 2012-2013, 2017-2018), Fondation ARC (2013-2014, 2015-2016), Assoc. Laurette Fugain (2013-2014), Canceropôle PACA 2013, ANR (2008-2011 ; 2020-2022), A*MIDEX (Emergence 2015-2017, Interdisciplinary 2015-2017 and 2018-2021), GEFLUC Marseille (2015-2016), Institut Universitaire de France (2013-2018), Region PACA-INSERM fellowship (2013-2015), AVIESAN PFA (2019-2022), ITMO Cancer Prénéoplasique 2022-2024, 2 AMIDEX transfert projects (2022-2025).

- european (700K€): FP7 EUCAAD (2009-2013), ITN PDZnet (2016-2020)

- industrial (360K€): U3 Pharma, INSERM Transfert Proof of Concept (2011, 2011-2015), AMIDEX Transfert (2022-2024).

In addition, J.-P. Borg has also raised major fundings for its institutions (CRCM and Institut Paoli-Calmettes): Contrat Projet Etat-Région FIGHTCANCER (14.800K€, 2015-2020 and 2022-2027), Contrat Projet Etat-Région Cancer XXI (2.550K€, 2022-2027), Contrat Projet Etat-Région CRCM-Pharmacie (3.000K€, 2022-2027), Comité Départemental 13 Ligue Contre le Cancer for FIGHTCANCER (1.450K€, 2016-2021)

- Industries: AMGEN, ROCHE, Emergence Tx… (1.200K€, 2011-2022)

Scientific summary

Doctor in Pharmacy (1995, Marseille), PhD in Immunology (1995, Marseille, D. Birnbaum’s lab), Jean-Paul Borg was a post-doctoral fellow at Howard Hughes Medical Institute (Ann Arbor, MI, USA, Ben Margolis’s lab) from 1995 to 1998. From 1998 to 2006, he was an INSERM Investigator and then became Professor of Cell Biology at Aix-Marseille University (since 2006). He is Head of the “Cell Polarity, Cell Signalling and Cancer” team at CRCM since 2004 and Director of CRCM since 2012. Since 2007, he is the Scientific Director of Institut Paoli-Calmettes, one of the largest university-affiliated comprehensive cancer centers in France, and Head of the Department of Pathology. He is also co-coordinator of the Marseille Proteomic Platform labelled IBiSA since 2008 and senior member of Institut Universitaire de France. The major part of his scientific career has been focused on elucidating cell signalling pathways (tyrosine kinases, WNT) and molecular networks centred on cell polarity proteins in the field of cancer. His latest discoveries are related to non-canonical WNT pathway in breast cancer.

Image d’exemple